Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real-world experience.

Autor: Russell M; Division of Thyroid and Parathyroid Endocrine Surgery, Harvard Medical School, Boston, Massachusetts, USA.; Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA., Gild ML; Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.; Cancer Genetics Laboratory, Kolling Institute of Medical Research, Sydney, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Wirth LJ; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Robinson B; Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.; Cancer Genetics Laboratory, Kolling Institute of Medical Research, Sydney, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Karcioglu AS; Division of Thyroid and Parathyroid Endocrine Surgery, Harvard Medical School, Boston, Massachusetts, USA.; Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA.; Division of Otolaryngology-Head and Neck Surgery, North Shore University HealthSystem, Evanston, Illinois, USA.; Department of Surgery, North Shore University HealthSystem, Evanston, Illinois, USA.; The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA., Iwata A; Division of Thyroid and Parathyroid Endocrine Surgery, Harvard Medical School, Boston, Massachusetts, USA.; Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA.; Department of Otolaryngology-Head and Neck Surgery, Kaiser Permanente Santa Clara Medical Center, Santa Clara, California, USA., Athni TS; Harvard Medical School, Boston, Massachusetts, USA., Abdelhamid Ahmed AH; Division of Thyroid and Parathyroid Endocrine Surgery, Harvard Medical School, Boston, Massachusetts, USA.; Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA., Randolph GW; Division of Thyroid and Parathyroid Endocrine Surgery, Harvard Medical School, Boston, Massachusetts, USA.; Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA.; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Head & neck [Head Neck] 2024 Oct; Vol. 46 (10), pp. 2496-2507. Date of Electronic Publication: 2024 Mar 15.
DOI: 10.1002/hed.27735
Abstrakt: Background: Experience with targeted neoadjuvant treatment for locoregionally advanced thyroid cancer is nascent.
Methods: Multicenter retrospective case series examining targeted neoadjuvant treatment for locoregionally advanced thyroid cancer. The primary outcome was change in surgical morbidity as measured by two metrics developed for use in clinical trials to characterize surgical complexity and morbidity. Secondary outcomes included percentage of patients proceeding to surgery and percentage receiving an R0/R1 resection.
Results: Seventeen patients with varied molecular alterations, pathologies, and treatment regimens were included. Mean surgical complexity scores decreased between time points for baseline and postneoadjuvant treatment, postneoadjuvant treatment and surgery, and between baseline and surgery. Eleven patients (64.7%) underwent surgical resection, with 10 (58.8%) receiving an R0/R1 resection.
Conclusions: Neoadjuvant treatment of advanced thyroid cancer improves resectability and decreases the morbidity of required surgical procedures. However, treatment is not uniformly effective.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: